|
IDefine attends Ultragenyx Rare Entrepreneur Bootcamp
Ultragenyx, a biopharmaceutical company involved in the development of novel products for treatment of rare genetic diseases, has been advising rare disease non-profits on an ad hoc basis for years.
However, in 2017, Ultragenyx decided to develop a more formal curriculum on the rare drug development process, and the “Rare Bootcamp” was born. Since then, more than 65 patient and family organizations have participated in the Bootcamp event series.
To ensure that the bootcamps are
personal and impactful, only a small
number of organizations that have typically already started their drug development journey are invited to attend.
IDefine was invited and represented
at the two-and-a-half-day event in Novato, Calif., by
Geoff Rhyne, CEO, and Eric Scheeff,
chief scientific officer (CSO).
“It's an honor to be invited because
it means that IDefine is viewed as
ready enough as an organization to
really hear this message,” said
Scheeff. “It was exciting to get the
invitation and a golden opportunity
that we couldn't miss. My
expectations were high, and they
were massively exceeded.” |
|
